Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.16
BIOC's Cash to Debt is ranked lower than
89% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. BIOC: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
BIOC' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 1.86 Max: No Debt
Current: 0.16
Equity to Asset -1.39
BIOC's Equity to Asset is ranked lower than
98% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. BIOC: -1.39 )
Ranked among companies with meaningful Equity to Asset only.
BIOC' s Equity to Asset Range Over the Past 10 Years
Min: -18.63  Med: -0.03 Max: 0.83
Current: -1.39
-18.63
0.83
F-Score: 4
Z-Score: -90.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -858.26
BIOC's Operating margin (%) is ranked lower than
91% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. BIOC: -858.26 )
Ranked among companies with meaningful Operating margin (%) only.
BIOC' s Operating margin (%) Range Over the Past 10 Years
Min: -1227100  Med: -9635.78 Max: -858.26
Current: -858.26
-1227100
-858.26
Net-margin (%) -876.22
BIOC's Net-margin (%) is ranked lower than
91% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. BIOC: -876.22 )
Ranked among companies with meaningful Net-margin (%) only.
BIOC' s Net-margin (%) Range Over the Past 10 Years
Min: -1362900  Med: -11247.71 Max: -876.22
Current: -876.22
-1362900
-876.22
ROE (%) -1825.67
BIOC's ROE (%) is ranked lower than
99% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. BIOC: -1825.67 )
Ranked among companies with meaningful ROE (%) only.
BIOC' s ROE (%) Range Over the Past 10 Years
Min: -1825.67  Med: -976.38 Max: -976.38
Current: -1825.67
-1825.67
-976.38
ROA (%) -228.80
BIOC's ROA (%) is ranked lower than
95% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. BIOC: -228.80 )
Ranked among companies with meaningful ROA (%) only.
BIOC' s ROA (%) Range Over the Past 10 Years
Min: -694.81  Med: -659.5 Max: -197.64
Current: -228.8
-694.81
-197.64
ROC (Joel Greenblatt) (%) -1645.32
BIOC's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. BIOC: -1645.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2717.73  Med: -1614.63 Max: -1249.59
Current: -1645.32
-2717.73
-1249.59
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:GENE, OTCPK:VRTT, NAS:CAPN, NAS:HTGM, NAS:DRIO, NAS:APPY, NAS:ROSG, OTCPK:MNLIF, NAS:ROKA, OTCPK:MDIT, NAS:ATOS, NAS:SGNL, NAS:CBMX, OTCPK:LEDIF, NAS:TBIO, OTCPK:BTHCF, NAS:BASI, OTCPK:MHTX, NAS:IDXG, OTCPK:MYAN » details
Traded in other countries:B001.Germany,
Biocept Inc is a cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample or liquid biopsy.

Ratios

vs
industry
vs
history
P/S 2.99
BIOC's P/S is ranked higher than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. BIOC: 2.99 )
Ranked among companies with meaningful P/S only.
BIOC' s P/S Range Over the Past 10 Years
Min: 2.6  Med: 33.5 Max: 89.45
Current: 2.99
2.6
89.45
Current Ratio 0.35
BIOC's Current Ratio is ranked lower than
95% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. BIOC: 0.35 )
Ranked among companies with meaningful Current Ratio only.
BIOC' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 2.89 Max: 10.2
Current: 0.35
0.02
10.2
Quick Ratio 0.25
BIOC's Quick Ratio is ranked lower than
96% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. BIOC: 0.25 )
Ranked among companies with meaningful Quick Ratio only.
BIOC' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 2.78 Max: 10.09
Current: 0.25
0.02
10.09
Days Inventory 23.32
BIOC's Days Inventory is ranked higher than
78% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. BIOC: 23.32 )
Ranked among companies with meaningful Days Inventory only.
BIOC' s Days Inventory Range Over the Past 10 Years
Min: 9.26  Med: 16.71 Max: 23.71
Current: 23.32
9.26
23.71
Days Sales Outstanding 14.61
BIOC's Days Sales Outstanding is ranked higher than
98% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. BIOC: 14.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.61  Med: 30.19 Max: 1825
Current: 14.61
14.61
1825
Days Payable 98.54
BIOC's Days Payable is ranked higher than
69% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.52 vs. BIOC: 98.54 )
Ranked among companies with meaningful Days Payable only.
BIOC' s Days Payable Range Over the Past 10 Years
Min: 50.27  Med: 241.4 Max: 22179.12
Current: 98.54
50.27
22179.12

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.09
BIOC's Price/Median PS Value is ranked higher than
95% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. BIOC: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 1 Max: 2.02
Current: 0.09
0.08
2.02
Earnings Yield (Greenblatt) (%) -99.25
BIOC's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. BIOC: -99.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -560.3  Med: 0 Max: 0
Current: -99.25
-560.3
0

More Statistics

Revenue (TTM) (Mil) $2.15
EPS (TTM) $ -2.63
Short Percentage of Float13.79%
52-Week Range $0.74 - 5.64
Shares Outstanding (Mil)17.50

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 3 6 12
EPS ($) -1.77 -0.89 -0.88
EPS w/o NRI ($) -1.77 -0.89 -0.88
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for BIOC

Headlines

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

More From Other Websites
9:47 am Biocept announces study results for its blood-based PD-L1 assay, which demonstrate 'the... Dec 07 2016
Biocept Presents Robust Analytical Validation Study Results for its PD-L1 Liquid Biopsy Test at the... Dec 07 2016
Teladoc November Visits Set Record: Why is Stock Suffering? Dec 07 2016
ETFs with exposure to Biocept, Inc. : December 5, 2016 Dec 05 2016
BIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Dec 02 2016
Biocept to Present at the LD Micro Main Event Nov 21 2016
BIOCEPT INC Financials Nov 18 2016
ETFs with exposure to Biocept, Inc. : November 14, 2016 Nov 14 2016
BIOCEPT INC Files SEC form 10-Q, Quarterly Report Nov 10 2016
Biocept, Inc. :BIOC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
Biocept Reports 2016 Third Quarter Financial Results Nov 09 2016
BIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 09 2016
Biocept Reports 2016 Third Quarter Financial Results Nov 09 2016
Q3 2016 Biocept Inc Earnings Release - After Market Close Nov 09 2016
BIOCEPT INC Files SEC form 8-K, Termination of a Material Definitive Agreement Nov 04 2016
Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9,... Oct 31 2016
Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9,... Oct 31 2016
BIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Oct 28 2016
Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications Oct 27 2016
Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)